XML 63 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statement of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Cash Flows from Operating Activities:    
Net loss $ (86,848) $ (41,659)
Adjustments to reconcile net loss to net cash used in operating activities:    
Issuance of common stock 3,787 135,657 [1]
Stock-based compensation 9,268 2,202
Depreciation and amortization 184 103
Non-cash lease expense 184  
Change in fair value of warrant liability (4,231) 0
Net amortization on marketable securities (4,593) (933)
Net loss (gain) on marketable securities 80 (218)
Change in operating assets and liabilities (net of assets and liabilities acquired in the Merger)    
Prepaid expenses and other current assets (2,416) (727)
Interest receivable on marketable securities (1,947) (264)
Accounts payable 1,861 34
Accrued expenses 7,452 2,921
Deferred rent (157) 146
Net cash used in operating activities (68,190) (36,529)
Cash Flows from Investing Activities:    
Purchases of marketable securities (609,300) (143,289)
Proceeds from sale of marketable securities 154,913 70,606
Proceeds from investment held to maturity   2,508
Purchases of property and equipment (282) (145)
Net cash (used in) provided by investing activities (454,669) (70,320)
Cash Flows from Financing Activities:    
Proceeds from the Merger, net of offering costs paid (see Note 3) 624,769  
Proceeds from issuance of stock, net of issuance costs   135,657
Proceeds from issuance of common stock under ESPP 308  
Proceeds from exercises of options 450  
Deferred financing costs   (2,522)
Net cash provided by financing activities 625,527 133,135
Net increase in cash and cash equivalents 102,668 26,286
Cash and cash equivalents, beginning of the period 29,755 3,469
Cash and cash equivalents, end of the period 132,423 29,755
Non-cash operating activity:    
Right-of-use asset obtained in exchange for operating lease liability 3,917  
Non-cash investing and financing activity:    
Issuance of common stock for in-process research and development 3,787  
Deferred financing costs in accounts payable and accrued expenses $ 0 $ 403
[1] Reflected net of deemed dividend and beneficial conversion feature (see note 8)